Travere gains on full FDA approval for kidney drug Filspari [Seeking Alpha]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Seeking Alpha
The once-daily oral medication developed by Travere ( TVTX ) in partnership with Ligand Pharmaceuticals ( NASDAQ: LGND ) was granted the FDA's accelerated approval in Feb. 2023 to reduce proteinuria in adults with IgA nephropathy, a rare progressive kidney disease. While accelerated approval was based on the surrogate marker of proteinuria, long-term confirmatory results from the company's PROTECT study backed its full approval. “Full approval now enables physicians to confidently prescribe FILSPARI more broadly as a once-daily, oral, non-immunosuppressive treatment, that can provide superior preservation of kidney function and replace current standard of care,” said Travere ( TVTX CEO Eric Dube. Recommended For You Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy [Yahoo! Finance]Yahoo! Finance
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyBusiness Wire
- Ligand to Present at H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
- Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Benchmark Co. from $95.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 8/6/24 - Beat
LGND
Sec Filings
- 9/19/24 - Form 4
- 9/18/24 - Form 4
- 8/30/24 - Form 4
- LGND's page on the SEC website